Human B-cell receptor recognizing dengue virus serotype 3 envelope protein (DENV3-E BCR)

The Human B-cell receptor recognizing dengue virus serotype 3 envelope protein (DENV3-E BCR) is a specialized membrane-bound immunoglobulin that plays a pivotal role in the adaptive immune system's defense against Dengue Virus Serotype 3 (DENV3). These receptors are responsible for identifying and binding to specific epitopes on the DENV3 envelope (E) protein, which is the major surface protein involved in viral attachment and fusion with host cell membranes (Pierson & Diamond, 2020). Upon antigen binding, the BCR triggers signaling pathways that lead to B-cell activation, clonal expansion, and the secretion of high-affinity neutralizing antibodies (Murphy & Weaver, 2016). In clinical medicine, these receptors are the primary targets for dengue vaccines, such as TAK-003, which aim to induce long-lasting protective immunity (Wilder-Smith, 2020). However, a significant challenge in targeting these receptors is the risk of antibody-dependent enhancement (ADE), where non-neutralizing or cross-reactive antibodies from a previous infection or vaccination can facilitate viral entry into myeloid cells, increasing the risk of severe dengue (Katzelnick et al., 2017). Consequently, therapeutic development focuses on eliciting BCR responses that are highly specific to DENV3 or broadly neutralizing across all four serotypes to avoid pathogenic outcomes.

Other names

DENV3 envelope-specific B-cell receptorAnti-DENV3 E protein BCRDengue virus type 3 envelope protein receptorHuman B-cell receptor for DENV3-E epitopes

Vaccines act as immunogens that bind to and activate these B-cell receptors to induce a protective humoral immune response, while therapeutic monoclonal antibodies may be designed to mimic the binding of these receptors to the virus to neutralize infection (Wilder-Smith, 2020; Pierson & Diamond, 2020).